FDA Approves Congenital Hyperinsulinism Treatment


ABG-023 overcomes the limitations glucagon because it remains stable in solutions.

rare disease, diabetes, hyperinsulinism

The US Food and Drug Administration (FDA) has granted an orphan drug designation for ABG-023, a solution stable, soluble glucagon analog designed to treat congenital hyperinsulinism (CHI).

The new treatment, developed by AmideBio, overcomes the limitations of glucagon, a proven effective treatment CHI that is rendered impractical for long-term administration because it is instable in solution.

CHI is a rare genetic disease affecting newborns and children, resulting in persistent hypoglycemia, which can lead to serious neurological complications such as seizures and brain damage. The disease causes a defect in the pancreas that can result in the patient having severe hypoglycemia because of the over production of insulin.

CHI impacts approximately 1 in every 50,000 new births annually.

The existing treatment options often necessitate the surgical intervention of partial or full pancreatectomies, which can result in the patient developing type 1 diabetes.

"This orphan drug designation is an important step for AmideBio's development of ABG-023 and for CHI patients and their parents, Pawel Fludzinski, CEO and President of AmideBio, said in a statement. “Glucagon has been shown to be a potentially game-changing treatment for these patients if it can be more readily administered, including for use in pumps. Our initial studies of ABG-023 have shown it to have great promise in overcoming the shortfalls of glucagon without sacrificing efficacy.”

AmideBio currently has a pipeline of novel biotherapeutics targeting metabolic disease that is generated by leveraging core competencies in intelligent design of drug candidates together with BioPure technology to deliver high purity and difficult-to-manufacture peptides of any length with purity.

Related Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Signs and Symptoms of Connective Tissue Disease
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
A panel of 5 cardiovascular experts
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
© 2024 MJH Life Sciences

All rights reserved.